Vohra Lubna M, Farooqi Nifasat, Jiwani Uswa, Ali Danish
Lubna M. Vohra, FCPS, Department of Surgery, Aga Khan University Hospital Karachi, Pakistan.
Nifasat Farooqi, FCPS, Department of Surgery, Aga Khan University Hospital Karachi, Pakistan.
Pak J Med Sci. 2024 Jan-Feb;40(1Part-I):8-13. doi: 10.12669/pjms.40.1.7360.
Breast-conserving surgery (BCS) with adjuvant radiotherapy remains the standard of care for early breast cancers in Pakistan. We sought to compare the outcomes of BCS with oncoplastic surgery (OPS), a relatively infrequent approach to breast cancer treatment in the country.
This retrospective cohort study was conducted at Aga Khan University Hospital and Ziauddin Hospital in Karachi. Patients who had biopsy-proven Stage-I to III breast cancer and underwent either OPS or BCS between August 1, 2016, and December 31, 2021, were identified and followed for 30 days. Data were collected by reviewing patient files and electronic records.
A total of 481 patients were included in the study, where 204 (42.4%) underwent BCS and 277 (57.6%) underwent OPS. Mean tumor volume (146.8 vs. 90.4 cm3), and postoperative complications (2.2 % vs. 0%) were higher in OPS while the frequency of positive margins was greater in the BCS group (15.7 % vs. 2.2 %). There were no significant differences in the histologic type of tumor between the two groups.
OPS is a valid alternative approach to breast cancer treatment that can be offered to women with early stage, locally advanced, multifocal or tumors at complex locations owing to the reduced occurrence of positive margins and thus lowered re-excision rates.
保乳手术(BCS)联合辅助放疗仍是巴基斯坦早期乳腺癌的标准治疗方法。我们试图比较保乳手术与肿瘤整形手术(OPS)的治疗效果,肿瘤整形手术在该国是一种相对不常用的乳腺癌治疗方法。
这项回顾性队列研究在卡拉奇的阿迦汗大学医院和齐亚乌丁医院进行。确定2016年8月1日至2021年12月31日期间经活检证实为I至III期乳腺癌且接受了肿瘤整形手术或保乳手术的患者,并对其进行30天的随访。通过查阅患者档案和电子记录收集数据。
共有481例患者纳入研究,其中204例(42.4%)接受了保乳手术,277例(57.6%)接受了肿瘤整形手术。肿瘤整形手术的平均肿瘤体积(146.8 vs. 90.4 cm³)和术后并发症(2.2% vs. 0%)更高,而保乳手术组切缘阳性的发生率更高(15.7% vs. 2.2%)。两组肿瘤的组织学类型无显著差异。
肿瘤整形手术是一种有效的乳腺癌治疗替代方法,由于切缘阳性发生率降低,从而降低了再次切除率,可用于治疗早期、局部晚期、多灶性或位于复杂部位的肿瘤的女性患者。